Core Insights - The company, Ruizhi Pharmaceutical, reported a decrease in the number of shareholders to 37,038 as of February 10, 2026, down by 376, or 1.0% from January 30, 2026 [1][2] - The average number of shares held per shareholder increased slightly from 13,300 to 13,400, with an average market value of 151,700 yuan per shareholder [1][2] - Compared to the industry average, Ruizhi Pharmaceutical's shareholder count is lower, with the medical services sector averaging 45,900 shareholders and an average market value of 351,100 yuan [1][2] Stock Performance - From January 30 to February 10, 2026, the stock price of Ruizhi Pharmaceutical increased by 8.05%, despite a reduction in shareholder count [1][2] - Over the preceding periods, the stock experienced fluctuations, including a decline of 3.33% from January 20 to January 30, 2026, and a notable increase of 14.54% from January 10 to January 20, 2026 [2] Capital Flow - During the period from January 30 to February 10, 2026, the company experienced a net outflow of 10.08 million yuan from institutional investors, while retail investors contributed a net inflow of 2.50 million yuan [4]

Core Insights - Recently, Ruizhi Pharmaceutical and Megia Technology officially signed a strategic cooperation agreement aimed at "building an intelligent biomanufacturing ecosystem to lead industry transformation" [1] - The collaboration will leverage Megia's AI-Agent technology and Ruizhi's advanced preclinical research capabilities along with high-quality data assets to create an "AI-driven automated laboratory for biomedicine" that is both evolvable and deployable [1] - This partnership marks a new phase in the evolution of AI from being an auxiliary tool to becoming a core infrastructure, systematically enhancing the quality and efficiency of drug development and establishing a benchmark project for AI automation in innovative drug research [1]

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical's shareholders have reduced their holdings due to personal financial needs, while the company has entered a strategic partnership to enhance drug development efficiency through AI technology [1][2]. Group 2 - Shareholders Liang Yufeng and Yu Xianwen have collectively reduced their holdings by 1.3894 million shares, bringing their ownership below 5% [1]. - The company has signed a strategic cooperation agreement with Meijia Technology to build an "AI-driven automated laboratory for biomedicine," aiming to combine AI technology with preclinical research capabilities [1]. - In the past 7 trading days, Ruizhi Pharmaceutical's stock price has increased by 1.83%, with a high of 11.42 yuan and a low of 10.77 yuan, closing at 11.10 yuan on February 12 [2].

Core Insights - The company has been focusing on innovation in the CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector since the appointment of Hu Ruilian as Chairman and CEO [1] - The company has developed a comprehensive service system that includes target discovery, process development, preclinical research, commercial production, and global submission, leveraging its core capabilities in CRO and CDMO [1] - The business scope has expanded to include new modalities such as ADC/XDC (Antibody-Drug Conjugates/Antibody-Drug Conjugates), small nucleic acids, and peptides, as well as chemical and biological drugs, forming a global R&D and production service network [1] Industry Trends - The pharmaceutical R&D outsourcing industry is entering a new development phase, driven by advancements in innovative drug development towards new modalities and the deep integration of AI technology with drug manufacturing [3]

Group 1 - The pharmaceutical research outsourcing industry is entering a new development stage with the integration of innovative drug development and AI technology [1] - The company has been focusing on innovation in the CXO (Contract Research and Manufacturing Outsourcing) field since the new CEO took over [1] - The company has established a comprehensive service system covering target discovery, process development, preclinical research, commercial production, and global submission [1] Group 2 - The business scope has expanded to include new modality drugs such as ADC/XDC (antibody-drug conjugates), small nucleic acids, and peptides, as well as chemical and biological drugs [1] - The company has formed a global research and production service network [1]

Group 1 - The core point of the article is that Ruizhi Pharmaceutical has reported its shareholder count as of January 30, which stands at 37,414 households [2]

证券代码：300149 证券简称：睿智医药 公告编号：2026-04 睿智医药科技股份有限公司 关于持股 5%以上股东减持至 5%以下暨权益变动的提示性公告 股东梁玉凤、于显文保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动系公司股东梁玉凤女士、于显文先生按减持计划减持公司股 份，导致其持有的公司股份减少，不触及要约收购，不会导致公司控股股东、实 际控制人发生变化，不会对公司治理结构及持续经营产生重大影响。 2、本次权益变动后，梁玉凤女士持有公司股份 24,898,160 股，占公司总股本 的比例为 4.99999%，不再是公司持股 5%以上的股东；于显文先生持有公司股份 24,898,100 股，占公司总股本的比例为 4.99998%，不再是公司持股 5%以上的股 东。 睿智医药科技股份有限公司（以下简称"公司"）于2026年1月15日披露了《关 于持股5%以上股东减持股份的预披露公告》（公告编号：2026-01），公司股东梁 玉凤女士计划在减持公告披露之日起十五个交易日后的三 ...

睿智医药科技股份有限公司 简式权益变动报告书 上市公司名称：睿智医药科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：睿智医药 股票代码：300149 信息披露义务人：梁玉凤 住所/通讯地址：广州市越秀区大北新街 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则的任何条款，或与之相冲突。 三、依据《证券法》、《收购管理办法》的规定，本报告书已全面披露信息 披露义务人在睿智医药科技股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没 有通过任何其他方式增加或减少其在睿智医药科技股份有限公司中拥有权益的 股份。 四、本次权益变动是根据本报告书所载明的资料进行的。除本信息披露义务 人外，没有委托或者授权其它任何人提供未在本报告书列载的信息和对本报告书 做出任何解释或者说明。 五、信息披露义务人承诺本报告不存在虚假记载、误导性陈述或重大遗漏， 并对其真实性、准确性和完整性承担个别和连带的法律责任。 | | 信息披露义务人声明 2 | | --- | --- | | 第一节 | 释 义 4 | | 第二节 | ...

上市公司名称：睿智医药科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：睿智医药 简式权益变动报告书 睿智医药科技股份有限公司 一、信息披露义务人依据《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司收购管理办法》（以下简称《收购管理办法》）、《公开发行证券的 公司信息披露内容与格式准则第15号—权益变动报告书》及相关的法律、法规和 规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则的任何条款，或与之相冲突。 股票代码：300149 信息披露义务人：于显文 股权变动性质：股份减少（持股比例降至 5%以下） 住所/通讯地址：广东省中山市东区起湾南道 46 号宝利大厦 本报告书签署日期：2026 年 2 月 9 日 1 信息披露义务人声明 三、依据《证券法》、《收购管理办法》的规定，本报告书已全面披露信息 披露义务人在睿智医药科技股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没 有通过任何其他方式增加或减少其在睿智医药科技股份有限公司中拥有权益的 股份。 四、本次权 ...

睿智医药（300149）科技股份有限公司(以下简称"睿智医药")作为一家专注于生物药、化学药一站式研 发生产服务的创新药企，秉持着"全方位赋能医药创新，让生命更早遇见希望"的使命，多年来在生物医 药领域持续深耕。 近日，睿智医药发布了2025年年度业绩预告。公告显示，公司2025年度归母净利润预计在1230.00万元 至1845.00万元之间，与上年同期亏损2.26亿元相比，业绩实现扭亏为盈。 面对竞争日趋白热化的CXO(医药合同外包服务)行业，睿智医药积极重塑发展战略，主动寻求破局之 道。一方面，深耕整包服务模式、持续加码前沿技术研发构建核心壁垒；另一方面，布局全球化运营网 络、深挖新兴市场价值，拓宽增长空间。该公司以技术革新为矛，以全周期服务为盾，在全球医药研发 创新赛道上加速前行。 近日，睿智医药董事长胡瑞连就公司战略转型成效、全球市场布局以及未来发展规划等问题，接受了 《证券日报》记者的专访。 从"分包"到"整包"的 战略跃迁 当前，国内CRO(医药研发合同外包服务机构)行业正处于挑战与机遇并存的关键转型期。 胡瑞连直言，行业的本质正在发生根本性变化。"过去行业比拼的是规模与成本，企业承接单一环节的 ...